Evidence map›Paper›PMID 28430990›Full record

ArticleJournal of radiation research2017

Three-dimensional dose prediction and validation with the radiobiological gamma index based on a relative seriality model for head-and-neck IMRT.

Noriaki Hamatani, Iori Sumida, Yutaka Takahashi, Michio Oda, Yuji Seo, Fumiaki Isohashi, Keisuke Tamari, Kazuhiko Ogawa

Abstract readValidation Study
In one paragraph

Article in Journal of radiation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noriaki HamataniDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Iori SumidaDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Yutaka TakahashiDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Michio OdaDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Yuji SeoDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Fumiaki IsohashiDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Keisuke TamariDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.
Kazuhiko OgawaDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, 2-2 (D10) Yamada-oka, Suita, Osaka 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study proposes a quality assurance (QA) method incorporating radiobiological factors based on the QUANTEC-determined tumor control probability and the normal tissue complication probability (NTCP) of head-and-neck intensity-modulated radiation therapy (HN-IMRT). Per-beam measurements were conducted for 20 cases using a 2D detector array. Three-dimensional predicted dose distributions within targets and organs at risk were reconstructed based on the per-beam QA results derived from differences between planned and measured doses. Under the predicted dose distributions, the differences between the physical and radiobiological gamma indices (PGI and RGI, respectively) based on the relative seriality (RS) model were evaluated. The NTCP values in the RS and Niemierko models were compared. The dose covers 98% (D98%) of the clinical target volume (CTV) decreased by 3.2% (P < 0.001), and the mean dose of the ipsilateral parotid increased by 6.3% (P < 0.001) compared with the original dose. RGI passing rates in the CTV and brain stem were greater than PGI ones by 5.8% (P < 0.001) and 2.0% (P < 0.001), respectively. The RS model's average NTCP values for the ipsilateral and contralateral parotids under the original dose were smaller than those of the Niemierko model by 9.0% (P < 0.001) and 7.0% (P < 0.001), respectively. The 3D predicted dose evaluation with RGI based on the RS model was introduced for QA of HN-IMRT, leading to dose evaluation for each organ with consideration of the radiobiological effect. This method constitutes a rational way to perform QA of HN-IMRT in clinical practice.

Indexed as

Gamma RaysRadiotherapy, Intensity-ModulatedDose-Response Relationship, RadiationHead and Neck NeoplasmsHumansProbabilityRadiotherapy Planning, Computer-AssistedIMRTNTCPQAradiobiological gamma index (RGI)TCP

Identifiers

PMID28430990
PMCPMC5737806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.